BR112021025537A2 - Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica - Google Patents
Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásicaInfo
- Publication number
- BR112021025537A2 BR112021025537A2 BR112021025537A BR112021025537A BR112021025537A2 BR 112021025537 A2 BR112021025537 A2 BR 112021025537A2 BR 112021025537 A BR112021025537 A BR 112021025537A BR 112021025537 A BR112021025537 A BR 112021025537A BR 112021025537 A2 BR112021025537 A2 BR 112021025537A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- gilteritinib
- venetoclax
- midostaurin
- azacitidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
- A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2103/00—Materials or objects being the target of disinfection or sterilisation
- A61L2103/05—Living organisms or biological materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864413P | 2019-06-20 | 2019-06-20 | |
| PCT/US2020/038772 WO2020257671A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025537A2 true BR112021025537A2 (pt) | 2022-03-03 |
Family
ID=71528047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025537A BR112021025537A2 (pt) | 2019-06-20 | 2020-06-19 | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica |
| BR112021025375A BR112021025375A2 (pt) | 2019-06-20 | 2020-06-19 | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025375A BR112021025375A2 (pt) | 2019-06-20 | 2020-06-19 | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220249528A1 (https=) |
| EP (2) | EP3986403A1 (https=) |
| JP (2) | JP2022537551A (https=) |
| KR (2) | KR20220050874A (https=) |
| CN (2) | CN114727996A (https=) |
| AU (2) | AU2020297596A1 (https=) |
| BR (2) | BR112021025537A2 (https=) |
| CA (2) | CA3143719A1 (https=) |
| IL (2) | IL289115A (https=) |
| MX (2) | MX2021015992A (https=) |
| WO (2) | WO2020257671A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| EP3740580A4 (en) | 2018-01-19 | 2021-10-20 | Duke University | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS |
| WO2022187288A2 (en) * | 2021-03-01 | 2022-09-09 | Duke University | Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness |
| US20250281510A1 (en) * | 2021-04-05 | 2025-09-11 | Pinotbio, Inc. | Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax |
| IL308318A (en) * | 2021-05-11 | 2024-01-01 | Abbvie Inc | Dosage regimens of VENETOCLAX for use in the treatment of MYELODYSPLASTIC syndromes in combination with a CYP3A inhibitor and AZACITIDINE |
| IL308321A (en) * | 2021-05-11 | 2024-01-01 | Abbvie Inc | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
| WO2023063784A1 (ko) * | 2021-10-14 | 2023-04-20 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물 |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3692983T3 (pl) * | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
| KR102400920B1 (ko) * | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| MX2017002875A (es) | 2014-09-08 | 2017-05-30 | Celgene Corp | Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1. |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| KR102699521B1 (ko) | 2015-10-15 | 2024-08-26 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| LT3371152T (lt) | 2015-11-05 | 2021-04-12 | Celgene Quanticel Research, Inc. | Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui |
| CA3017408C (en) | 2016-03-15 | 2025-08-19 | Oryzon Genomics, S.A. | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| KR20200020899A (ko) | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법 |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2020
- 2020-06-19 JP JP2021575387A patent/JP2022537551A/ja active Pending
- 2020-06-19 WO PCT/US2020/038772 patent/WO2020257671A1/en not_active Ceased
- 2020-06-19 BR BR112021025537A patent/BR112021025537A2/pt not_active IP Right Cessation
- 2020-06-19 CA CA3143719A patent/CA3143719A1/en active Pending
- 2020-06-19 CA CA3143711A patent/CA3143711A1/en active Pending
- 2020-06-19 JP JP2021575509A patent/JP2022537384A/ja active Pending
- 2020-06-19 EP EP20737778.9A patent/EP3986403A1/en active Pending
- 2020-06-19 AU AU2020297596A patent/AU2020297596A1/en not_active Abandoned
- 2020-06-19 EP EP20737783.9A patent/EP3986404A1/en not_active Withdrawn
- 2020-06-19 CN CN202080058723.0A patent/CN114727996A/zh active Pending
- 2020-06-19 CN CN202080057984.0A patent/CN115066243A/zh active Pending
- 2020-06-19 AU AU2020296179A patent/AU2020296179A1/en not_active Abandoned
- 2020-06-19 MX MX2021015992A patent/MX2021015992A/es unknown
- 2020-06-19 US US17/620,541 patent/US20220249528A1/en active Pending
- 2020-06-19 US US17/620,545 patent/US12447171B2/en active Active
- 2020-06-19 WO PCT/US2020/038760 patent/WO2020257665A1/en not_active Ceased
- 2020-06-19 MX MX2021015993A patent/MX2021015993A/es unknown
- 2020-06-19 BR BR112021025375A patent/BR112021025375A2/pt active Search and Examination
- 2020-06-19 KR KR1020227001609A patent/KR20220050874A/ko not_active Ceased
- 2020-06-19 KR KR1020227001605A patent/KR20220024639A/ko not_active Ceased
-
2021
- 2021-12-19 IL IL289115A patent/IL289115A/en unknown
- 2021-12-19 IL IL289110A patent/IL289110A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022537384A (ja) | 2022-08-25 |
| CN115066243A (zh) | 2022-09-16 |
| WO2020257665A1 (en) | 2020-12-24 |
| CA3143719A1 (en) | 2020-12-24 |
| KR20220050874A (ko) | 2022-04-25 |
| BR112021025375A2 (pt) | 2022-02-01 |
| CA3143711A1 (en) | 2020-12-24 |
| US20220249529A1 (en) | 2022-08-11 |
| US20220249528A1 (en) | 2022-08-11 |
| JP2022537551A (ja) | 2022-08-26 |
| CN114727996A (zh) | 2022-07-08 |
| AU2020297596A1 (en) | 2022-02-03 |
| US12447171B2 (en) | 2025-10-21 |
| KR20220024639A (ko) | 2022-03-03 |
| MX2021015993A (es) | 2022-04-06 |
| EP3986403A1 (en) | 2022-04-27 |
| EP3986404A1 (en) | 2022-04-27 |
| WO2020257671A1 (en) | 2020-12-24 |
| IL289115A (en) | 2022-02-01 |
| MX2021015992A (es) | 2022-04-06 |
| AU2020296179A1 (en) | 2022-02-03 |
| IL289110A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021025537A2 (pt) | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica | |
| MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| JOP20190285A1 (ar) | استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| MX2024000349A (es) | Compuestos y usos de los mismos. | |
| CY1117317T1 (el) | Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων | |
| BR112019001615A2 (pt) | métodos e composições para tratar mielofibrose | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| BRPI0606542A2 (pt) | métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab | |
| ECSP10010007A (es) | Tratamiento con ligandos alpha-7-selectivos | |
| NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
| PA8784001A1 (es) | Oxazolidinonas sustituidas y su uso | |
| DK1830881T3 (da) | Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| BR112015029367A2 (pt) | terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas | |
| CR20240363A (es) | Compuestos y métodos para el tratamiento de infecciones virales. | |
| WO2019209948A8 (en) | Compounds and uses thereof | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| MX393900B (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2024006769A (es) | Compuestos y usos de los mismos. | |
| EP3986554A4 (en) | Targeting melanocortin 3 receptor for treatment/prevention of eating, metabolism, and/or emotional disorders | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2832 DE 15-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |